Dr. John Cush RheumNow
5 years 10 months ago
Warfarin and Risk of Hip and Knee Replacements with Dr. Mrinalini Dey ( @DrMiniDey) #ACR20. https://t.co/znTxIx1QQZ https://t.co/elQlChwr0N
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg
Dr. John Cush RheumNow
5 years 10 months ago
Let us know your thoughts on our article titled "Undifferentiated Autoinflammatory Syndrome Called VEXAS"
https://t.co/afNK3UuZef #ACR20 https://t.co/fp2sX9w894
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @synovialjoints : Can we find Axial Spa (FaxSpa) using social media? This study used an online screening tool (A-tool) on social media in patients with back pain. 42% had a positive screen and referred for review @RheumNow #ACR20 Abstr#1894
Dr. John Cush RheumNow
5 years 10 months ago
Dr. Kathryn Dao ( @KDAO2011) reviews abstract #0533 presented at #ACR20 on male osteoporosis.
https://t.co/Z0NLcJzslV https://t.co/SSoIA7Eetg
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @DrMiniDey : Late breaking: in older #rheumatoidarthritis patients, those taking MTX have 2x risk of #VTE compared to those on HCQ. Important to consider #thromboembolic risk factors when starting new RA treatment.
Abs#2000 #ACR20
https://t.co/lMYlXgaHyE https://t.co/0Fdone9yb3
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @drdavidliew : Mavrilimumab (anti-GM-CSF) in GCA, phase 2
GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying??
PNL induction then enrol+PNL taper
GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62%
ABSTL06 https://t.co/xxjd2lTSUe https://t.co/uuBOnbk6Ab
Dr. John Cush RheumNow
5 years 10 months ago
Did you know we have podcast? Search Rheum Now on Apple/Android or listen directly through the link below.
https://t.co/wjBWCrKL34 https://t.co/yhZ2wyujA0
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @synovialjoints : The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @ejdein1:Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20
Dr. Jonathan Kay leads an international panel discussion on the new ACR RA guidelines and several practice-changing abstracts presented at the 2020 ACR meeting. Panelists include Dr. Kathryn Dao, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway and Dr. Sheila Reyes.
Dr. John Cush RheumNow
5 years 10 months ago
New podcast up! On this episode titled #ACR20 Epilogue, we review more ACR 2020 abstracts and present a new plan to learn or take in ACR20 content. Listen via the link below or download on Apple/Android podcasts.
https://t.co/yj1WIcMtfb https://t.co/YjdYpPZNIC
This podcast features a discussion of autoinflammatory and Still's disease abstracts from virtual ACR 2020. Dr. Jack Cush is joined by a panel of experts including Drs. Olga Petryna, Bella Metha and Michael Ombrello.
You can listen to this podcast on SoundCloud, iTunes, Apple Car Play, Google podcasts or by clicking below
Dr. John Cush RheumNow
5 years 10 months ago
Video:COVID and Rheumatic Disease Patients with Dr. Kevin Winthrop #ACR20
https://t.co/VHIibPNDXG https://t.co/0OVIXzX6su
